Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) dated March 14, 2017, announces the publication of the Company's Annual Report for the year ended December 31, 2016. The filing serves to distribute the 2016 Annual Report, 2016 Annual Summary, and the 2017 Notice of Annual General Meeting to shareholders and regulatory authorities. The document references unaudited preliminary results released on February 8, 2017, but does not contain the full financial statements within this specific text.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained in the referenced 2016 Annual Report and the preliminary results announcement from February 8, 2017, which are not included in the source text provided.
However, the filing does disclose the following dividend schedule:
- Q4 2016 Dividend: Payment date April 13, 2017.
- Q1 2017 Dividend: Payment date July 13, 2017.
- Q2 2017 Dividend: Payment date October 12, 2017.
- Q3 2017 Dividend: Payment date January 11, 2018.
Material Changes and Operational Context
While specific financial variances are not listed, the filing highlights several material operational and strategic contexts affecting the business:
- Patent Expirations: The patent for the combination of active substances in Seretide/Advair has expired. Generic versions have launched in European markets, and Abbreviated New Drug Applications (ANDAs) for Seretide/Advair Diskus were approved in the US in January 2017, with potential market entry as early as March 2017.
- Regulatory Environment: The Company notes ongoing scrutiny regarding data integrity, third-party oversight, and evolving tax laws (including OECD BEPS projects) which may impact the effective tax rate.
- Legal Proceedings: GSK is a defendant in various product liability lawsuits and class actions. The Company has resolved an Anti-Bribery and Corruption (ABAC) inquiry with US authorities in 2016, while an inquiry by UK authorities remains ongoing.
Guidance, Outlook, and Risks
The filing includes a cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks and uncertainties. The document details the following principal risks and management's mitigating activities:
- Patient Safety: Risks related to adverse events and product liability. Mitigation includes a global safety surveillance system and a Global Safety Board with authority to stop clinical trials.
- Intellectual Property: Risks of patent loss and generic competition. Mitigation involves a Global Patents group focused on enforcement and monitoring international patent law.
- Product Quality: Risks of non-compliance with Good Manufacturing Practices (cGMP). Mitigation includes a single Pharmaceutical Quality System (PQS) and rigorous third-party supplier audits.
- Financial Controls: Risks related to tax law changes and treasury activities. Mitigation includes a Finance Risk and Controls Centre of Excellence and a Disclosure Committee.
- Anti-Bribery and Corruption: Risks of non-compliance with ABAC legislation. Mitigation includes an enterprise-wide ABAC programme with zero-tolerance policies and enhanced training.
- Commercialisation: Risks of failing to execute strategy or comply with promotional laws. Mitigation includes changes to sales compensation models to focus on interaction quality rather than sales volume.
- Supply Continuity: Risks of supply chain disruption. Mitigation includes business continuity planning and safety stock strategies for critical products.
Investor Verification Checklist
- Verify the specific revenue, profit, and cash flow figures in the full 2016 Annual Report and the February 8, 2017 preliminary results announcement, as they are not present in this filing.
- Review Note 46 ('Legal proceedings') in the Annual Report for detailed status updates on product liability lawsuits and the ongoing UK ABAC inquiry.
- Assess the financial impact of the Seretide/Advair patent expiration and the timing of generic entry in the US market.
- Confirm the Company's effective tax rate and any potential adjustments due to ongoing international tax reforms and disputes.
- Examine the details of the integration of former Novartis businesses into GSK's control and reporting framework.